Novartis to Collaborate with Glenmark to Promote, Commercialize and Distribute Three Respiratory Therapies for COPD in Brazil

Shots:

• Novartis signs an exclusive commercialization agreement with Glenmark to commercialize three respiratory therapies i.e, Seebri, Onbrize and Ultibro for treating COPD in Brazil. Novartis will be responsible for the manufacturing of therapies
• The focus of the collaboration is to bolster Glenmark’s respiratory franchise and to expand its respiratory portfolio in Brazil. The agreement will be effective from July 01, 2019
• Novartis’ Seebri (glycopyrronium bromide) is long-acting muscarinic receptor antagonist (LAMA), Onbrize (indacaterol) is an ultra-long-acting, rapid onset β(2)-adrenoceptor agonist and Ultibro is a combination of indacaterol and glycopyrronium, indicated to treat COPD in adults

Click here to read full press release/ article | Ref: Glenmark | Image: Corporate Ethos